ReCode Therapeutics

About ReCode Therapeutics

• ReCode Therapeutics is a clinical-stage genetic medicines company developing therapeutics for genetically defined diseases with no existing treatment options, including cystic fibrosis and primary ciliary dyskinesia.
• The company utilizes its selective organ targeting (SORT) lipid nanoparticle (LNP) platform to enable precise delivery of mRNA and gene correction therapeutics to target organs and cells beyond the liver.

ReCode Therapeutics is listed on Rocketlist with 4 active roles. The company is categorized as Genetic Medicines in BioTech. ReCode Therapeutics is at Growth stage, with a B2B business model, headquartered in Menlo Park, United States. ReCode Therapeutics was founded in 2015 and has 105 employees. ReCode Therapeutics has raised $321M. Active roles are refreshed daily from public hiring sources.

Open roles at ReCode Therapeutics (4)